Enzyme Multiplied Immunoassay Technique (EMIT)

Meet Grant, a new lab technician. He wants to know more about EMIT technology and how it works. His colleague Maya is happy to explain Maya let's Grant know that EMIT stands for Enzyme Multiplied Immuno Assay Technique. This proven technology is used by Siemens chemistry and integrated instruments to run drugs of abuse testing. Emit uses an enzyme labeled drug and antibody bond to produce its results. It all begins in the lab with a urine sample that may or may not have drugs in it. Let's see what happens. The sample is first combined with reagent one, which contains glucose 6, phosphate or G6P, nicotinamide adenine dinucleotide or NAD plus and antibodies specific to the drug or drugs being tested. The sample and reagent are mixed together. When the drug is present, the drug antigens bind to the antibody binding sites of the drug specific antibody. Then reagent 2 is added which contains drug labeled glucose 6 phosphate dehydrogenase or G6 PDH, an enzyme bound to the drug being screened. The final reaction mixture is mixed and incubated. Since antibody binding sites are already occupied by the drug antigen, the enzyme labeled drug is free, allowing it to react with the G6P. As the G6P is broken down by the enzyme, hydrogen ions are released. NAD plus then combines with free hydrogen to form NADH. The amount of NADH produced as a result of the enzyme multiplying reaction is directly proportional to the amount of drug in the sample. Since NADH absorbs light, we measure its presence spectrophotometrically. A high absorbance reading means NADH production, which gives BRAN a positive test result. Maya reminds Grant that treatment starts with a test. Once a lab gets the result, the ordering physician will take action. Depending on the patient's circumstances, results may lead to adjustments in treatment, counseling, or criminal justice consequences. Grant can see how important testing is for patient treatment. Still, he wonders what happens when a drug isn't present in the sample. Maya explains that similarly reagent one is added to the sample and mixed reagent 2 is then added. Since the antibody binding sites haven't bound with the drug being tested, they bind with the enzyme labeled drug. Therefore enzyme multiplying activity decreases. Most G6P remains unchanged and the mid assay detects little NADH production producing a low absorbance reading, thus a negative test result. Grant thanks Maya for helping him understand EMIT technology and how it produces results. He's excited to use this trusted technology to help patients start their treatment journey.

50 SIEMENS Healthineers Enzyme Multiplied Immunoassay Technique (EMIT) Ab Reagent 1 Reagent 2 EMIT Enzyme Multiplied Immunoassay Technique Years Amphetamines Cocaine Ecstasy Opiates Oxycodone Sample ??? G6P NAD+ G6PDH NADH Positive LAB RESULTS Negative - X X Siemens Healthcare Diagnostics Inc ., 2020 Atellica CH, Dimension EXL, Dimension Vista, ADVIA Chemistry, Viva-ProE and and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc ., or its affiliates. All other trademarks and brands are the property of their respective owners. Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local epresentative for availability. Please contact your local representative for availability. Please note that the learning material is for training purposes only. For the proper use of the software or hardware, please always use the Operator Manual or Instructions for Use (hereinafter collectively "Operator Manual") issued by Siemens Healthineers. This material is to be used as training material only and shall by no means substitute the Operator Manual. Any material used in this training will not be updated on a regular basis and does not necessarily reflect the latest version of the software and hardware available at the time of the training. The Operator Manual shall be used as your main reference, in particular for relevant safety information like warnings and cautions. Please note: Some functions shown in this material are optional and might not be part of your system. Certain products, product related claims or functionalities (hereinafter collectively "Functionality") may not (yet) be commercially available in your country. Due to regulatory requirements, the future availability of said Functionalities in any specific country is not guaranteed. Please contact your local Siemens Healthineers sales representative for the most current information. The reproduction, transmission or distribution of this training or its contents is not permitted without express written authority. Offenders will be liable for damages. All names and data of patients, parameters and configuration dependent designations are fictional and examples only. All rights, including rights created by patent grant or registration of a utility model or design, are reserved. Unrestricted | Published by Siemens Healthineers AG | c Siemens Healthineers AG, 2024 Siemens Healthineers HQ | Siemens Healthineers AG Siemensstr. 3 91301 Forchheim Germany Phone: +49 9191 18-0 siemens-healthineers.com